Table 1

Baseline characteristics of metformin-intolerant and metformin-tolerant groups

Intolerant group (n = 164)Tolerant group (n = 1,356)P*
Age (years)68.8 ± 9.758.4 ± 10.6<0.001
Age at diagnosis (years)63.5 ± 9.955.2 ± 10.3<0.001
Females/males (% female)94/70 (57.3)545/811 (40.2)<0.001
Weight (kg)81.7 ± 15.592.1 ± 18.3<0.001
BMI (kg/m2)30.4 ± 5.432.6 ± 6.1<0.001
HbA1c<0.001
 %8.1 (7.7–9.2)8.8 (7.8–9.9)
 mmol/mol65 (61–77)73 (62–85)
Creatinine (µmol/L)87.4 ± 14.487.2 ± 14.40.831
Creatinine clearance (mL/min)74.4 (57.4–91.4)97.7 (77.0–120.7)<0.001
Antidiabetes drug naive86 (52.4)831 (61.3)0.029
Use of OCT1-inhibiting drugs83 (50.6)450 (33.2)<0.001
Metformin daily dose (mg)1,000 (1,000–1,000)1,000 (1,000–1,500)<0.001
  • Data are reported as the mean ± SD, median (interquartile range), or n (%), unless otherwise indicated.

  • *P values refer to the significance of t test, Mann-Whitney U test, or a χ2 test for data presented as the mean ± SD, median (interquartile range), or n (%), respectively.

  • †Number of individuals concomitantly treated with OCT1-inhibiting drugs, including proton pump inhibitors, tricyclic antidepressants, citalopram, verapamil, diltiazem, doxazosin, spironolactone, clopidogrel, rosiglitazone, quinine, tramadol, and codeine.